Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
eNq1mF1v2jAUhu/5FVEudkfSUOhgS6g21m5Ircbaok27QSY5KWbGTv3Bx379HEJXOjnqavBlYuc9xz7Hj18lPl8viLcELjCjiR8FJ74HNGUZpveJP767bHb9834jnqMleprW0vOCKPK9lCAhEr8cDaaAqAh+XF99Av09cL/f8GI2nUMqn81TEpPgCxKza1SUc7x4yXDmLUDOWJb4hZLbt14sJNdZ9FeM/xIFSiEOd2/2R+eT9v77OCzF/kNVCeBXiN4bRYFaaaaKc6BygCTcM76pyffUShuLGxBM8RRGSM5GnC1xBpkxRI6IAKsg+Sq7Bb4kIMsgRvFwni6ElTiao/UNPAzNSX/QowO5ls2TZvS22+6cnnR6rVbnzCoU39sqcxX0IsJ0ErXa0Vm3GwIN0RQTnG8sazNiXCLiqCpYDJ43lqM4HB5erH6GRUHQJpiLwnarEEd6GLg+/u4WUq7gjmsgEb1n/+hTRUj4yqzHO1w4yrik0YApKmuoMb613YgBoxLW9RW1A51c73oRgzie7G9GzZAfqSnBqS3SNHQUCDm+GdYT7Zgw+IgEjLk7GnzHNGMrcXzK7FfVUfbFFpRG0YJn0aTV655FnY71IfqpW6jmhrlQnBUQav5gcQhWhjRnhwJFd6VZ6rEnj9aOW5/DUkSgxuk0Ldmi+/DRmDnrdHenqBowin6+uLNtj28K+OZ2+2iUxlnyt7B24HVBc92MLyVeHdukmGhb1u2dtt+gRfH+0UInlna5EnXilhU3M2YmZSHeheFqtQpmSDQF0vsZ5Lz+Djg3Lv0Yy9fAfaqmO0PvxABUhqiCraPUp9Ut+roy2h7clyzCobZ39/3OXhtjSK7ggFpUjHdG4uHF8eH+5HmdpT16hhh3Ybb+FEnMqCvfpKZGxcOuE11Xesk1IL7mOa75wVLbl3FY/dzpN+Kw/LHTb/wBRt8ATQ==
UfpCGKbNfQ90LbSN
